Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: Gynecol Oncol. 2014 Jun 24;134(3):581–590. doi: 10.1016/j.ygyno.2014.06.013

Table 2.

Estimated survival rate at year 5 and 95% confidence interval

Characteristics		Overall Survival			Progression Free Survival
Characteristics		Estimate year 5 survival rate	95% Confidence Interval	P-value	Estimate year 5 survival rate	95% Confidence Interval	P-value
iCTCs	Negative	0.650	0.422-1.000	0.0219	0.628	0.413-0.955	0.0024
iCTCs	Positive	0.334	0.223-0.499	0.0219	0.171	0.094-0.312	0.0024
Stage^* iCTCs	I+II & Negative	1.000	1.000-1.000	0.0136	0.889	0.706-1.000	0.0010
	I+II & Positive	0.750	0.426-1.000		0.600	0.293-1.000
	III+IV & Negative	0.200	0.035-1.000		0.200	0.035-1.000
	III+IV & Positive	0.306	0.197-0.476		0.136	0.066-0.279
Debulking^** iCTCs	Optimal Deb & Negative	0.646	0.418-0.998	0.0037	0.606	0.387-0.947	0.0009
	Optimal Deb & Positive	0.3777	0.2509- 0.5686		0.1963	0.1081- 0.3563
	Suboptimal Deb & Positive	0.1481	0.0244- 0.8999		0	NA
Platinum Sensitivity^*** iCTCs	Not Sensitive & Negative	0.000	NA	<0.000 1	0.000	NA	<0.0001
	Not Sensitive & Positive	0.000	NA		^§ 0.050	0.007-0.338
	Sensitive & Negative	0.750	0.503-1.000		0.700	0.467-1.000
	Sensitive & Positive	0.549	0.365-0.827		0.187	0.076-0.461

^*

Stage - I+II and III+IV subgroups.

^**

Debulking - Optimal Debulking and Suboptimal Debulking subgroups.

^***

Platinum Sensitivity - Not Sensitive and Sensitive subgroups.

^§

The last censoring was before year 5.